Patrick Walsh Email & Phone Number

Wellesley, MA, US

Guildford, Surrey, GB

Wilmington, NC, US

Princeton, New Jersey, US

Independent Director and serves on the compensation committee.

Provides consulting, strategic advisory and due diligence review.

Reggio Emilia, IT

Chairman of the Lifecore Innovation Committee

Tustin, California, US

Independent Director and serves as Chair of the Compensation committee and a member of the Nominating Committee.

TriPharm is a CDMO providing aseptic fill and finish drug manufacturing services for biologic or small volume parenteral projects in liquid, lyophilized, syringe and vial product offerings. Alcami acquired TrIPharm Services in 2020.

East Rutherford, New Jersey, US

Recruited by private equity firm Ampersand Capital to lead Avista Pharma Solutions, which became a preferred CDMO to the pharmaceutical industry in less than 4 years and was acquired by Cambrex Corp in January 2019.

Wilmington, NC, US

Recruited by private equity firm Water Street Healthcare Partners to lead the successful turn-around of AAIPharma Services Corp. In four years, AAI tripled its customer base, doubled its revenues and increased its profitability more than 10-fold culminating in an outstanding return on invested capital upon its acquisition in October 2013.The business.

Chief Executive Officer of a privately-heId, venture capital backed company that was acquired by Organon Biosciences while still at an "A" round valuation. Lead a three-tranche financing round of over $25 million, completed several key licensing transactions and intellectual property enhancements, hired a strong leadership team, secured cost-effective.

Led a senior team of executives involved in all aspects of a growing $400 million specialty pharmaceutical and contract service business. Explosive growth over a 4 year period resulted in the successful merger of Gensia and Sicor creating a profitable, vertically integrated global, specialty pharmaceutical company. Gensia Sicor business combination.

Originally hired by Lyphomed, then asked to assume greater leadership roles following LyphoMed's acquisition by Fujisawa Pharmaceuticals. Promoted 7 times over a 9 year period rising from District Sales Manager to eventually serving as Corporate VP leading the U.S. and international business groups for Fujisawa, USA. Reported directly to CEO of corporation.